Loader

Pathways

PathWhiz ID Pathway Meta Data

PW146703

Pw146703 View Pathway
drug action

Piperaquine Drug Metabolism Action Pathway

Homo sapiens

PW144708

Pw144708 View Pathway
drug action

Piperazine Drug Metabolism Action Pathway

Homo sapiens

PW146107

Pw146107 View Pathway
drug action

Piperonyl butoxide Drug Metabolism Action Pathway

Homo sapiens

PW144365

Pw144365 View Pathway
drug action

Pipobroman Drug Metabolism Action Pathway

Homo sapiens

PW128414

Pw128414 View Pathway
drug action

Pipotiazine Dopamine Antagonist Action Pathway

Homo sapiens
Pipotiazine acts as an antagonist (blocking agent) on different postsysnaptic receptors -on dopaminergic-receptors (subtypes D1, D2, D3 and D4 - different antipsychotic properties on productive and unproductive symptoms), on serotonergic-receptors (5-HT1 and 5-HT2, with anxiolytic, antidepressive and antiaggressive properties as well as an attenuation of extrapypramidal side-effects, but also leading to weight gain, fall in blood pressure, sedation and ejaculation difficulties), on histaminergic-receptors (H1-receptors, sedation, antiemesis, vertigo, fall in blood pressure and weight gain), alpha1/alpha2-receptors (antisympathomimetic properties, lowering of blood pressure, reflex tachycardia, vertigo, sedation, hypersalivation and incontinence as well as sexual dysfunction, but may also attenuate pseudoparkinsonism - controversial) and finally on muscarinic (cholinergic) M1/M2-receptors (causing anticholinergic symptoms like dry mouth, blurred vision, obstipation, difficulty/inability to urinate, sinus tachycardia, ECG-changes and loss of memory, but the anticholinergic action may attenuate extrapyramidal side-effects).

PW145485

Pw145485 View Pathway
drug action

Pipotiazine Drug Metabolism Action Pathway

Homo sapiens

PW176351

Pw176351 View Pathway
metabolic

Pipotiazine Predicted Metabolism Pathway

Homo sapiens
Metabolites of sildenafil are predicted with biotransformer.

PW128404

Pw128404 View Pathway
drug action

Pipotiazine Serotonin antagonist Action Pathway

Homo sapiens
Pipotiazine acts as an antagonist (blocking agent) on different postsysnaptic receptors -on dopaminergic-receptors (subtypes D1, D2, D3 and D4 - different antipsychotic properties on productive and unproductive symptoms), on serotonergic-receptors (5-HT1 and 5-HT2, with anxiolytic, antidepressive and antiaggressive properties as well as an attenuation of extrapypramidal side-effects, but also leading to weight gain, fall in blood pressure, sedation and ejaculation difficulties), on histaminergic-receptors (H1-receptors, sedation, antiemesis, vertigo, fall in blood pressure and weight gain), alpha1/alpha2-receptors (antisympathomimetic properties, lowering of blood pressure, reflex tachycardia, vertigo, sedation, hypersalivation and incontinence as well as sexual dysfunction, but may also attenuate pseudoparkinsonism - controversial) and finally on muscarinic (cholinergic) M1/M2-receptors (causing anticholinergic symptoms like dry mouth, blurred vision, obstipation, difficulty/inability to urinate, sinus tachycardia, ECG-changes and loss of memory, but the anticholinergic action may attenuate extrapyramidal side-effects).

PW132497

Pw132497 View Pathway
metabolic

Pipradrol Drug Metabolism

Homo sapiens
Pipradrol is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. Pipradrol passes through the liver and is then excreted from the body mainly through the kidney.

PW146387

Pw146387 View Pathway
drug action

Pipradrol Drug Metabolism Action Pathway

Homo sapiens